Holen Sie sich die Stockscreener-App
0.4102
3.64%
0.0144
Handel nachbörslich:
.41
-0.0002
-0.05%
Schlusskurs vom Vortag:
$0.3958
Offen:
$0.4
24-Stunden-Volumen:
621.87K
Relative Volume:
0.61
Marktkapitalisierung:
$10.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.56M
KGV:
-0.6311
EPS:
-0.65
Netto-Cashflow:
$-22.29M
1W Leistung:
-4.38%
1M Leistung:
-19.35%
6M Leistung:
-46.34%
1J Leistung:
-86.09%
1-Tages-Spanne:
$0.3999
$0.425
1-Wochen-Bereich:
$0.36
$0.425
52-Wochen-Spanne:
$0.34
$3.199
BiomX Inc Stock (PHGE) Company Profile
Firmenname
BiomX Inc
Sektor
Branche
Telefon
972 7 23942377
Adresse
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Vergleichen Sie PHGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.4102 | 11.23M | 0 | -26.56M | -22.29M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-15 | Eingeleitet | Ladenburg Thalmann | Buy |
BiomX Inc Aktie (PHGE) Neueste Nachrichten
What drives BiomX Inc. stock priceFree Stock Market Knowledge Sharing - Autocar Professional
BiomX Inc. Stock Analysis and ForecastExceptional market performance - PrintWeekIndia
What analysts say about BiomX Inc. stockUnmatched market gains - jammulinksnews.com
Is BiomX Inc. a good long term investmentConsistent wealth multiplication - jammulinksnews.com
Should I buy BiomX Inc. stock before earningsHigh Return Stock Alerts - Newser
How BiomX Inc. stock performs during market volatilityFree Signals Group - Newser
What makes BiomX Inc. stock price move sharplyFree Access to Stock Community - Newser
Why BiomX Inc. stock attracts strong analyst attentionCapital Efficient Investment Tips - Newser
BiomX stock holds Buy rating at H.C. Wainwright as Phase 2b trial begins - Investing.com Canada
BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target - Investing.com India
BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target By Investing.com - Investing.com South Africa
BiomX Stock Drops 7.23% Despite Phase 2b Trial Milestone - AInvest
BiomX announces successful initiation of Phase 2b trial - TipRanks
Market Alert: BiomX Trading Surges Following Phase 2b Trial Initiation in Cystic Fibrosis Program - openPR.com
Biomx Inc. shares fall 5.21% after-hours following the initiation of Phase 2b trial for BX004. - AInvest
BiomX Initiates Phase 2b Trial for BX004, a Phage Therapy Targeting Antibiotic-Resistant Lung Infections in Cystic Fibrosis Patients. - AInvest
Biomx Inc. Announces Successful Initiation of Phase 2B Trial with First Patient Dosed in Bx004 Program in Patients with Cystic Fibrosis - MarketScreener
BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy - Investing.com Australia
BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment - MSN
BiomX Doses First Patient in Phase 2b of Cystic Fibrosis Trial - MarketScreener
BiomX begins phase 2b trial for phage therapy targeting CF infections - Investing.com Australia
BiomX begins phase 2b trial for phage therapy targeting CF infections By Investing.com - Investing.com South Africa
BiomX Inc. Initiates First Patient Dosing in Phase 2b Trial for BX004 Targeting Antibiotic-Resistant Lung Infections in Cystic Fibrosis Patients - Nasdaq
BiomX Announces Successful Initiation of Phase 2b Trial - GlobeNewswire
Breakthrough Cystic Fibrosis Treatment Enters Phase 2b Trial After 14% Complete Infection Clearance - Stock Titan
BiomX (NYSEMKT:PHGE) Trading Down 43.3% – Here’s What Happened - Defense World
BiomX Publishes Promising Phase 1b/2a Trial Results - TipRanks
BiomX’s “Bacteria-Eating Virus” Therapy Shows 500-Fold Reduction in Deadly CF Infections: Company Announces Major Scientific Validation in Key Publication - newsblaze.com
BiomX announces publication on BX004 Phase 1b/2a Part 1 data - TipRanks
BiomX Announces Publication in Nature Communications of - GlobeNewswire
Nature Communications Validates BiomX's Breakthrough: 500-fold Bacteria Reduction in Cystic Fibrosis Trial - Stock Titan
Red White & Bloom Brands Provides Update on Status of Annual Filings - The Globe and Mail
This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret - FinancialContent
This $13M Biotech Has $40M In Pentagon Funding Here's Why Biomx Could Be Biotech's Best-Kept Secret - MenaFN
PHGE SEC FilingsBiomx Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections - citybuzz -
BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says - FinancialContent
BiomX Highlights Progress in Phage Therapy Advancements - TipRanks
BiomX (NYSEAMERICAN:PHGE) Shares Down 4.3% – Here’s What Happened - Defense World
Biomx stock plunges to 52-week low, hitting $0.47 By Investing.com - Investing.com South Africa
Biomx stock plunges to 52-week low, hitting $0.47 - Investing.com Australia
BiomX (NYSEMKT:PHGE) Stock Price Down 32.6% – What’s Next? - Defense World
Bacteriophage Therapy Market is Booming Worldwide |Enbiotix,Micreos,BiomX - openPR.com
Finanzdaten der BiomX Inc-Aktie (PHGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):